PBD Biotech is developing a simple blood test that could identify those at risk of tuberculosis disease progression, before the person becomes infectious, enabling lifesaving treatment and protecting family members.
Tuberculosis is the world’s most lethal infectious disease, and it impacts the most vulnerable in society. It is difficult to detect at an early stage, so millions of people are dying from this preventable, treatable disease.
The Actiphage TB diagnostic, which is currently going through clinical trials, has the potential to be a game-changer in the global fight to End TB.
PBD Biotech CEO, Jane Theaker, says: “All the team are passionate about making a difference and putting an end to this devastating disease. There are new treatments coming through and our test will make it easier to target therapy to reach the most vulnerable.
“The Social Impact category is new this year and it is a great way to highlight some very worthy enterprises. We are honoured to be considered alongside the Afro-Caribbean Commercial Science Network, Health Equity North, and The Christie NHS Foundation Trust.”
The winners for the Bionow Awards will be announced at a black-tie evening on the 7th March 2024 at The Concorde Centre, Manchester Airport.